Ocrelizumab, an anti-CD20 monoclonal antibody, targets mature B-cells. Almost 95% of the B-cell population has these antigenic epitopes after maturation and does not shed them, which is what makes it a potent marker for therapeutic purposes (cancer being a very common area of interest in this regard).
Read more about Ocrelizumab here: http://bit.ly/1JUBLqj
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?